14
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee

      letter
      1 , * , 1 , 1 , 1 ,   1 , 1 , 1 , 1 , 1 , 1 , 2 , 3 , 4 , 5 , 6 , 1 , 7 , 8 , 8 , 9 , 10 , 11 , 3 , 12 , 13 , 14 , 15 , 16 , 1 , 17
      British Journal of Cancer
      Nature Publishing Group
      cluster randomised controlled trial, screening, prostate cancer, prostate cancer mortality, cause of death, death certification, sensitivity, specificity

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Accurate cause of death assignment is crucial for prostate cancer epidemiology and trials reporting prostate cancer-specific mortality outcomes.

          Methods:

          We compared death certificate information with independent cause of death evaluation by an expert committee within a prostate cancer trial (2002–2015).

          Results:

          Of 1236 deaths assessed, expert committee evaluation attributed 523 (42%) to prostate cancer, agreeing with death certificate cause of death in 1134 cases (92%, 95% CI: 90%, 93%). The sensitivity of death certificates in identifying prostate cancer deaths as classified by the committee was 91% (95% CI: 89%, 94%); specificity was 92% (95% CI: 90%, 94%). Sensitivity and specificity were lower where death occurred within 1 year of diagnosis, and where there was another primary cancer diagnosis.

          Conclusions:

          UK death certificates accurately identify cause of death in men with prostate cancer, supporting their use in routine statistics. Possible differential misattribution by trial arm supports independent evaluation in randomised trials.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: not found
          • Article: not found

          THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

              Prostate cancer is a major public health problem with considerable uncertainties about the effectiveness of population screening and treatment options. We report the study design, participant sociodemographic and clinical characteristics, and the initial results of the testing and diagnostic phase of the Prostate testing for cancer and Treatment (ProtecT) trial, which aims to investigate the effectiveness of treatments for localised prostate cancer.
                Bookmark

                Author and article information

                Journal
                Br J Cancer
                Br. J. Cancer
                British Journal of Cancer
                Nature Publishing Group
                0007-0920
                1532-1827
                28 June 2016
                02 June 2016
                28 June 2016
                : 115
                : 1
                : 90-94
                Affiliations
                [1 ]School of Social and Community Medicine, University of Bristol , Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
                [2 ]Department of Health Sciences, University of York and the Hull York Medical School , YO10 5DD, UK
                [3 ]Urology Department, Royal United Hospital , Combe Park, Bath BA1 3NG, UK
                [4 ]Avon Primary Care Research Collaborative , South Plaza, Marlborough Street, Bristol BS1 3NX, UK
                [5 ]School of Social and Community Medicine, University of Bristol, Royal Hallamshire Hospital , Sheffield S10 2JF, UK
                [6 ]Department of Oncology, University of Cambridge, Addenbrooke's Hospital , Box 279 (S4), Cambridge CB2 0QQ, UK
                [7 ]School of Social and Community Medicine, University of Bristol, Freeman Hospital, High Heaton , Newcastle upon Tyne NE7 7DN, UK
                [8 ]Nuffield Department of Surgical Sciences, John Radcliffe Hospital , Oxford OX3 9DU, UK
                [9 ]University of Connecticut Health Center, Farmington, St Francis Hospital and Medical Center , Hartford, CT, USA
                [10 ]Department of Palliative Medicine, Bristol Haematology and Oncology Centre , Bristol BS2 8ED, UK
                [11 ]Department of Cellular Pathology, North Bristol NHS Trust, Southmead Hospital , Bristol BS10 5NB, UK
                [12 ]Department of Cellular Pathology, Royal Victoria Infirmary , Newcastle upon Tyne NE1 4LP, UK
                [13 ]Department of Clinical Science, Karolinska Institutet , Stokholm, Sweden
                [14 ]Harvard Radiation Oncology Program, Harvard Medical School, Massachusetts General Hospital , Boston, MA, USA
                [15 ]Department of Surgery, University College London , Gower Street, London WC1E 6BT, UK
                [16 ]Department of Urology, North Bristol NHS Trust, Southmead Hospital , Bristol BS10 5NB, UK
                [17 ]School of Social and Community Medicine, MRC/University of Bristol Integrative Epidemiology Unit, University of Bristol , Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK
                Author notes
                Article
                bjc2016162
                10.1038/bjc.2016.162
                4931376
                27253172
                3072742d-5e3e-4183-be85-93cad57f73a5
                Copyright © 2016 Cancer Research UK

                This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                History
                : 12 February 2016
                : 18 April 2016
                : 30 April 2016
                Categories
                Short Communication

                Oncology & Radiotherapy
                cluster randomised controlled trial,screening,prostate cancer,prostate cancer mortality,cause of death,death certification,sensitivity,specificity

                Comments

                Comment on this article